Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | 0.0118 | 0.7107 | 1 | |
Brugia malayi | celfurPC protein | 0.0118 | 0.7107 | 0.4795 |
Plasmodium falciparum | plasmepsin I | 0.0048 | 0 | 0.5 |
Plasmodium vivax | plasmepsin IV, putative | 0.0048 | 0 | 0.5 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.0089 | 0.4134 | 0.5817 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.0089 | 0.4134 | 0.4134 |
Toxoplasma gondii | aspartyl proteinase (eimepsin), putative | 0.0048 | 0 | 0.5 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0146 | 1 | 1 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0146 | 1 | 1 |
Toxoplasma gondii | aspartyl protease ASP1 | 0.0048 | 0 | 0.5 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0092 | 0.4443 | 0.4443 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0092 | 0.4443 | 0.6251 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0054 | 0.0602 | 0.5 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0089 | 0.4134 | 1 |
Plasmodium vivax | aspartyl proteinase, putative | 0.0048 | 0 | 0.5 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0089 | 0.4134 | 1 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0143 | 0.9655 | 0.9655 |
Echinococcus granulosus | furin | 0.0146 | 1 | 1 |
Plasmodium falciparum | plasmepsin VI | 0.0048 | 0 | 0.5 |
Plasmodium falciparum | plasmepsin II | 0.0048 | 0 | 0.5 |
Schistosoma mansoni | furin-1 (S08 family) | 0.0063 | 0.155 | 0.155 |
Loa Loa (eye worm) | hypothetical protein | 0.0146 | 1 | 1 |
Schistosoma mansoni | cathepsin D (A01 family) | 0.0143 | 0.9655 | 0.9655 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.0911 | 0.0911 |
Plasmodium falciparum | plasmepsin IV | 0.0048 | 0 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.